Welcome to our dedicated page for Bio-Path Hldgs SEC filings (Ticker: BPTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bio-Path Holdings, Inc. (BPTH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries that help explain complex documents. As a clinical-stage biotechnology company, Bio-Path uses its SEC reports to describe the status of its DNAbilize® RNAi nanoparticle platform, clinical trials for prexigebersen (BP1001), BP1001-A, BP1002, and BP1003, and the financial resources supporting these programs.
In annual reports (Form 10-K) and quarterly reports (Form 10-Q), Bio-Path discusses its clinical-stage pipeline, research and development expenses, operating losses, and going-concern risks. These filings also outline the company’s strategy to generate drug candidates from DNAbilize® and its need for additional capital. Notification filings such as Form 12b-25 explain delays in periodic reports and can reference management changes or other factors affecting reporting timelines.
Current reports on Form 8-K are especially important for BPTH, as they document material events such as leadership changes, board resignations, operational pauses, financing efforts, and strategic evaluations. One 8-K describes a company-wide operational pause, furloughs of most employees, and the possibility that Bio-Path may need to delay or eliminate programs, license or dispose of assets on less favorable terms, or potentially liquidate and dissolve the company if it cannot raise capital. Other 8-K filings detail changes in executive roles and board composition, as well as plans to seek financing and review the biotech portfolio.
The Form 25 filing for Bio-Path records the removal of its common stock from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Exchange Act, a key event in the company’s trading history. Through these and other filings, investors can follow developments related to listing status, capital structure, and operational plans.
Stock Titan’s interface surfaces these documents in chronological order and applies AI-generated highlights to help readers quickly identify disclosures about clinical progress, financial condition, going-concern language, and corporate actions. Users can review Forms 10-K, 10-Q, 8-K, 12b-25, and Form 25 to build a detailed picture of Bio-Path’s regulatory and financial history, as well as its risk profile as a clinical-stage biotech issuer.
On 20–22 June 2025, Bio-Path Holdings, Inc. (BPTH) disclosed a sequence of leadership departures and an immediate operational shutdown driven by acute liquidity constraints, according to its Form 8-K filing.
Founder Peter H. Nielsen resigned from every executive position—President, Chief Executive Officer, Chief Financial Officer, Treasurer, Principal Accounting Officer—as well as Chairman and director roles. Directors Heath Cleaver and Aline Sherwood also stepped down; both stated their decisions were not the result of disagreements with the Company or Board.
The remaining directors appointed Douglas P. Morris as Chairman with no compensatory changes. Concurrently the Board instituted a company-wide operational pause, furloughing most employees and suspending the majority of drug-development activities to conserve capital while it searches for new financing.
The filing reiterates prior warnings: without additional capital, Bio-Path may have to scale back or eliminate development programs, dispose of assets on unfavorable terms, or proceed to liquidation and dissolution. There is no assurance of securing funding on acceptable terms, if at all.
Overall, the 8-K signals elevated going-concern risk, abrupt leadership vacuum and potential value erosion for shareholders.